ClinicalTrials.gg
RecruitingNCT07864142BIMASUpdated Oct 7, 2026

First-Trimester Screening of Open Neural Tube Defects Using Biometrics and Maternal Serum Markers

An observational study in Neural Tube Defects (NTDs), sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Study summary

Open neural tube defects are congenital malformations associated with significant morbidity. Early detection during the first trimester remains a key challenge.

This retrospective monocentric study aims to evaluate the diagnostic performance of fetal biometrics (biparietal diameter and abdominal transverse diameter ratios) and maternal serum markers (beta-hCG and PAPP-A) for early screening of open neural tube defects. The study will assess the predictive value of these parameters individually and in combination to define optimal screening thresholds applicable in routine clinical practice

02

Conditions studied

  • Neural Tube Defects (NTDs)

Browse trials for

Keywords

  • Neural tube defects
  • Prenatal screening
  • First trimester
  • Fetal biometrics
  • Maternal serum markers
03

In context

Neural Tube Defects

47 studies on the registry are indexed under Neural Tube Defects; 9 are open to participants now.

This study's planned enrollment of 100 is above the median of 90 across 20 observational studies indexed under Neural Tube Defects.

Browse Neural Tube Defects studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women undergoing routine first-trimester ultrasound screening at Strasbourg University Hospitals, including both normal pregnancies and those complicated by open neural tube defects.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult pregnant woman (≥18 years)
  • First-trimester ultrasound performed at Strasbourg University Hospitals between 01/01/2011 and 31/12/2023
  • No written opposition to reuse of medical data for research purposes

Exclusion criteria

Exclusion Criteria:

  • Written opposition to reuse of medical data for research purposes
  • Multiple pregnancy
  • Presence of fetal growth abnormality, morphological or genetic anomaly during pregnancy
  • Crown-rump length \<45 mm or >84 mm at screening ultrasound
  • Missing data
  • Fetus with closed dysraphism
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Diagnostic performance of biometric ratios and serum markers

    Determination of optimal thresholds for BPD/TAD and BPD/PA ratios and maternal serum markers (beta-hCG and PAPP-A) for screening of open neural tube defects, by comparing their diagnostic performance alone and in combination using ROC analysis.

    Time frame: At first-trimester screening (retrospective data from 2011 to 2023)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Nov 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartActual
Sep 14, 2026
Primary completionEst.
Nov 14, 2026
CompletionEst.
Dec 14, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07864142
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Sep 14, 2026
Primary completion
Nov 14, 2026 (estimated)
Completion
Dec 14, 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

Chris Minella, MD
Contact
chris.minella@chru-strasbourg.fr
33 3 88 12 74 95

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion